<- Back to digest

BJJ - 2026-11-01 - Journal Article; Systematic Review; Meta-Analysis; Comparative Study

A comparison of the efficacy and safety of direct oral anticoagulants with low molecular weight heparin for venous thromboembolism prophylaxis after total hip arthroplasty : a systematic review and meta-analysis.

Mohammad HR, Rahman A, Muhammad IM, Gill SS, Selim A, Thomas G, Murray DW, Griffin XL

meta-analysisLOE In = 22 RCTs, 28,112 patientsN/A if not reported.

Topics

arthroplasty
PMID: 42966367DOI: 10.1302/0301-620X.108B11.BJJ-2026-0451.R2View on PubMed ->

Key Takeaway

DOACs reduce VTE risk by 38% (OR 0.62) versus LMWH after THA, with no difference in bleeding risk when restricted to UK-licensed agents and doses.

Summary Depth

Choose how much analysis to show on this article page.

Summary

This systematic review and meta-analysis of 22 RCTs compared DOAC versus LMWH VTE prophylaxis after elective THA. DOACs reduced overall VTE risk (OR 0.62, 95% CI 0.47–0.82) and DVT specifically (OR 0.60, 95% CI 0.42–0.86), with no difference in PE, reoperation, or mortality. When analysis was restricted to UK-licensed agents and doses, the bleeding signal seen in the overall DOAC cohort (OR 1.19) disappeared (OR 1.06, p=0.279), and projected NHS cost savings reached £8.6 million annually.

Key Limitation

Pooling across multiple DOAC agents with differing mechanisms, dosing regimens, and prophylaxis durations introduces clinical heterogeneity that may obscure agent-specific safety or efficacy differences.

Original Abstract

AIMS

To evaluate differences in the efficacy and safety of low molecular weight heparin (LMWH) and direct oral anticoagulants (DOACs) used for venous thromboembolism (VTE) prophylaxis after elective total hip arthroplasty (THA).

METHODS

This systematic review and meta-analysis reviewed MEDLINE, Embase, and CENTRAL from conception to 13 December 2025, for any randomized controlled trials (RCTs) comparing the efficacy (VTE risk) and safety (bleeding risk) of LMWH and DOACs after elective THA. Pooled odds ratios (ORs) of VTE, bleeding, reoperation, and mortality risks were assessed.

RESULTS

A total of 22 RCTs involving 28,112 participants were included. The risk of VTE in the DOAC group was lower compared with the LMWH group (OR 0.62 (95% CI 0.47 to 0.82); p = 0.002), driven by a reduction in deep vein thrombosis (DVT) risk (OR 0.60 (95% CI 0.42 to 0.86); p = 0.008). The findings remained consistent in the subgroup analysis restricted to anticoagulants and dosages licensed for use in the UK. Overall bleeding risk was higher in the DOAC group (OR 1.19 (95% CI 1.03 to 1.38); p = 0.023), but no difference was seen when comparing only UK-licensed anticoagulants and doses (OR 1.06 (95% CI 0.95 to 1.18); p = 0.279). Reoperation risk (OR 1.21 (95% CI 0.75 to 1.93); p = 0.351) and mortality (OR 1.03 (95% CI 0.46 to 2.33); p = 0.937) did not differ between groups.

CONCLUSION

DOACs reduce the risk of VTE and DVT following elective THA compared with LMWH without increasing bleeding risk, for UK-licensed agents and doses. Switching to DOACs could save the NHS £8.6 million per year. New clinical trials are needed to compare the safety and efficacy of UK-licensed DOACs and LWMH with modern postoperative rehabilitation protocols.